Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by lonc17on May 09, 2024 8:54pm
138 Views
Post# 36032600

RE:RE:Panc Phase 3

RE:RE:Panc Phase 3This is pretty much the only thing they said in the entire call with regards to Panc Registrational Trial:

From Thomas H. 

Updating us on an update. This compmay gets worse every day. It's not a scam but damn close, IMO.
They do anything and everything they can to secure next quarter's paychecks. 

In closing I'd like to discuss our registrational plans for pela in pancreatic cancer. Our registrational strategy will focus on pela in combination with atezolizumab, gemcitabine and nab-paclitaxel in patients receiving first-line treatment for metastatic pancreatic cancer. We continued to develop a study protocol that utilizes an adaptive design building on the positive results from cohort 1 of the GOBLET study. We expect to provide an update on these plans this quarter.
<< Previous
Bullboard Posts
Next >>